Cardiac dysfunction and oxidative stress in the metabolic syndrome: An update on antioxidant therapies

Current Pharmaceutical Design

Volumn 19, Issue 27, 2013, Pages 4806-4817

  Ilkun, Olesya ^a   Boudina, Sihem ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Cardiac dysfunction; Insulin resistance; Metabolic syndrome; Mitochondrial dysfunction; Oxidative stress; Reactive oxygen species; Substrate utilization

Indexed keywords

ACETYLCYSTEINE; ADIPOCYTOKINE; ALLOPURINOL; ANTHOCYANIN; ANTIOXIDANT; BENDAVIA; CURCUMIN; FLAVONOID; GLYCOGEN; MELATONIN; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; NORPHENAZONE; POLYPHENOL; RESVERATROL; S 17834; SS 31; UBIDECARENONE; UNCLASSIFIED DRUG; VITAMIN;

ANTIOXIDANT ACTIVITY; ARTICLE; AUTOPHAGY; CARDIOMYOPATHY; DETOXIFICATION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DYSLIPIDEMIA; ENZYME GLYCOSYLATION; FIBROSIS; GENE TRANSFER; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID STORAGE; METABOLIC SYNDROME X; MITOCHONDRION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; CARDIOMYOPATHIES; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; HEART; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; MYOCARDIUM; OBESITY; OXIDATIVE STRESS;

EID: 84881320396     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319270003     Document Type: Article

References (180)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735-52.
2. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007 Feb; 92(2): 399-404.
3. Bugger H, Abel ED. Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci (Lond) 2008; 114(3): 195-210.
4. Nicolson GL. Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. J Cell Biochem 2007; 100(6): 1352-69.
5. Palmieri VO, Grattagliano I, Portincasa P, Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr 2006; 136(12): 3022-6.
6. Armutcu F, Ataymen M, Atmaca H, Gurel A. Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. Clin Chem Lab Med 2008; 46(6): 785-90.
7. Voulgari C, Moyssakis I, Papazafiropoulou A, et al. The impact of metabolic syndrome on left ventricular myocardial performance. Diabetes Metab Res Rev 2010; 26(2): 121-7.
8. Chinali M, de Simone G, Roman MJ, et al. Cardiac markers of preclinical disease in adolescents with the metabolic syndrome: the strong heart study. J Am Coll Cardiol 2008; 52(11): 932-8.
9. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161(7): 996-1002.
10. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347(5): 305-13.
11. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003; 49(3): 417-23.
12. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004; 18(14): 1692-700.
13. Kusminski CM, Shetty S, Orci L, Unger RH, Scherer PE. Diabetes and apoptosis: lipotoxicity. Apoptosis 2009; 14(12): 1484-95.
14. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc Med 2007; 17(6): 206-11.
15. Zeidan A, Javadov S, Karmazyn M. Essential role of Rho/ROCKdependent processes and actin dynamics in mediating leptininduced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc Res 2006; 72(1): 101-11.
16. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003; 108(6): 754-9.
17. Mohan V, Deepa R, Pradeepa R, et al. Association of low adiponectin levels with the metabolic syndrome--the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 2005; 54(4): 476-81.
18. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291(14): 1730-7.
19. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54(2): 534-9.
20. Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10(12): 1384-9.
21. Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45(2): 270-80.
22. Takeishi Y, Niizeki T, Arimoto T, et al. Serum resistin is associated with high risk in patients with congestive heart failure--a novel link between metabolic signals and heart failure. Circ J 2007; 71(4): 460-4.
23. Zhang MH, Na B, Schiller NB, Whooley MA. Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. J Card Fail 2011; 17(1): 24-30.
24. Frankel DS, Vasan RS, D'Agostino RB, Sr., et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009; 53(9): 754-62.
25. Chemaly ER, Hadri L, Zhang S, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol 2011; 51(2): 144-55.
26. Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52(3): 405-13.
27. Lamounier-Zepter V, Ehrhart-Bornstein M, Karczewski P, Haase H, Bornstein SR, Morano I. Human adipocytes attenuate cardiomyocyte contraction: characterization of an adipocytederived negative inotropic activity. FASEB J 2006; 20(10): 1653-9.
28. Lamounier-Zepter V, Look C, Alvarez J, et al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 2009; 105(4): 326-34.
29. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972 Nov 8; 30(6): 595-602.
30. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115(25): 3213-23.
31. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010 Mar; 11(1): 31-9.
32. Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977; 60(4): 884-99.
33. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22(4 Suppl A): 6A-13A.
34. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241(19): 2035-8.
35. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107(6): 539-57.
36. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25(4): 543-67.
37. Carugo S, Giannattasio C, Calchera I, et al. Progression of functional and structural cardiac alterations in young normotensive uncomplicated patients with type 1 diabetes mellitus. J Hypertens 2001; 19(9): 1675-80.
38. Falcao-Pires I, Hamdani N, Borbely A, et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 2011; 124(10): 1151-9.
39. Avendano GF, Agarwal RK, Bashey RI, et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 1999; 48(7): 1443-7.
40. Ma H, Li SY, Xu P, et al. Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 2009; 13(8B): 1751-64.
41. Dobrin JS, Lebeche D. Diabetic cardiomyopathy: signaling defects and therapeutic approaches. Expert Rev Cardiovasc Ther 2010; 8(3): 373-91.
42. Tang WH, Cheng WT, Kravtsov GM, et al. Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. Am J Physiol Cell Physiol 2010; 299(3): C643-53.
43. Connelly KA, Kelly DJ, Zhang Y, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 2007; 76(2): 280-91.
44. Miklos Z, Kemecsei P, Biro T, et al. Early cardiac dysfunction is rescued by upregulation of SERCA2a pump activity in a rat model of metabolic syndrome. Acta Physiol (Oxf) 2012; 205(3): 381-93.
45. Sakata S, Lebeche D, Sakata Y, et al. Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther 2006; 13(5): 987-96.
46. Xu KY, Zweier JL, Becker LC. Hydroxyl radical inhibits sarcoplasmic reticulum Ca(2+)-ATPase function by direct attack on the ATP binding site. Circ Res 1997; 80(1): 76-81.
47. Kantharidis P, Wang B, Carew RM, Lan HY. Diabetes complications: the microRNA perspective. Diabetes 2011; 60(7): 1832-7.
48. Feng B, Chen S, George B, Feng Q, Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 2010; 26(1): 40-9.
49. Hwang YC, Jee JH, Kang M, Rhee EJ, Sung J, Lee MK. Metabolic syndrome and insulin resistance are associated with abnormal left ventricular diastolic function and structure independent of blood pressure and fasting plasma glucose level. Int J Cardiol 2011 Mar 9.
50. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA 2005; 294(3): 334-41.
51. Belke DD, Betuing S, Tuttle MJ, et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002; 109(5): 629-39.
52. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 2003; 285(3): H1261-9.
53. McQueen AP, Zhang D, Hu P, et al. Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density. J Mol Cell Cardiol 2005; 39(6): 882-92.
54. Sena S, Hu P, Zhang D, et al. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. J Mol Cell Cardiol 2009; 46(6): 910-8.
55. Duncan JG. Peroxisome proliferator activated receptor-alpha (PPARalpha) and PPAR gamma coactivator-1alpha (PGC-1alpha) regulation of cardiac metabolism in diabetes. Pediatr Cardiol 2011; 32(3): 323-8.
56. Buchanan J, Mazumder PK, Hu P, et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005; 146(12): 5341-9.
57. Sloan C, Tuinei J, Nemetz K, et al. Central leptin signaling is required to normalize myocardial fatty acid oxidation rates in caloric-restricted ob/ob mice 2011; 60(5): 1424-34.
58. Peterson LR, Herrero P, McGill J, et al. Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes. Diabetes 2008; 57(1): 32-40.
59. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006; 55(2): 466-73.
60. Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009; 54(16): 1524-32.
61. Ouwens DM, Diamant M, Fodor M, et al. Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 2007; 50(9): 1938-48.
62. Menard SL, Croteau E, Sarrhini O, et al. Abnormal in vivo myocardial energy substrate uptake in diet-induced type 2 diabetic cardiomyopathy in rats. Am J Physiol Endocrinol Metab 2010; 298(5): E1049-57.
63. Boudina S, Bugger H, Sena S, et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009; 119(9): 1272-83.
64. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109(18): 2191-6.
65. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96(7): 2190-6.
66. Scheuermann-Freestone M, Madsen PL, Manners D, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003; 107(24): 3040-6.
67. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 2009; 54(20): 1891-8.
68. Kuo TH, Giacomelli F, Wiener J. Oxidative metabolism of Polytron versus Nagarse mitochondria in hearts of genetically diabetic mice. Biochim Biophys Acta 1985; 806(1): 9-15.
69. Boudina S, Sena S, Theobald H, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007; 56(10): 2457-66.
70. Boudina S, Sena S, O'Neill BT, Tathireddy P, Young ME, Abel ED. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 2005; 112(17): 2686-95.
71. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulinresistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 2007; 115(7): 909-17.
72. Nisoli E, Clementi E, Carruba MO, Moncada S. Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 2007; 100(6): 795-806.
73. Ren J, Pulakat L, Whaley-Connell A, Sowers JR. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) 2010; 88(10): 993-1001.
74. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8(2): 92-103.
75. Shen E, Li Y, Shan L, et al. Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes 2009 Oct; 58(10): 2386-95.
76. Nakamura H, Matoba S, Iwai-Kanai E, et al. p53 promotes cardiac dysfunction in diabetic mellitus caused by excessive mitochondrial respiration-mediated reactive oxygen species generation and lipid accumulation. Circ Heart Fail 2012; 5(1): 106-15.
77. Hansford RG, Zorov D. Role of mitochondrial calcium transport in the control of substrate oxidation. Mol Cell Biochem 1998; 184(1-2): 359-69.
78. Oliveira PJ, Seica R, Coxito PM, et al. Enhanced permeability transition explains the reduced calcium uptake in cardiac mitochondria from streptozotocin-induced diabetic rats. FEBS Lett 2003; 554(3): 511-4.
79. Medikayala S, Piteo B, Zhao X, Edwards JG. Chronically elevated glucose compromises myocardial mitochondrial DNA integrity by alteration of mitochondrial topoisomerase function. Am J Physiol Cell Physiol 2011; 300(2): C338-48.
80. Bugger H, Chen D, Riehle C, et al. Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic akita mice. Diabetes 2009; 58(9): 1986-97.
81. Hu Y, Suarez J, Fricovsky E, et al. Increased enzymatic OGlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J Biol Chem 2009 Jan 2; 284(1): 547-55.
82. Dabkowski ER, Baseler WA, Williamson CL, et al. Mitochondrial dysfunction in the type 2 diabetic heart is associated with alterations in spatially distinct mitochondrial proteomes. Am J Physiol Heart Circ Physiol 2010; 299(2): H529-40.
83. Essop MF, Chan WA, Hattingh S. Proteomic analysis of mitochondrial proteins in a mouse model of type 2 diabetes. Cardiovasc J Afr 2011; 22(4): 175-8.
84. Baseler WA, Dabkowski ER, Williamson CL, et al. Proteomic alterations of distinct mitochondrial subpopulations in the type 1 diabetic heart: contribution of protein import dysfunction. Am J Physiol Regul Integr Comp Physiol 2011; 300(2): R186-200.
85. Makino A, Suarez J, Gawlowski T, et al. Regulation of mitochondrial morphology and function by O-GlcNAcylation in neonatal cardiac myocytes. Am J Physiol Regul Integr Comp Physiol 2011; 300(6): R1296-302.
86. Nakai A, Yamaguchi O, Takeda T, et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007; 13(5): 619-24.
87. Terman A, Brunk UT. Autophagy in cardiac myocyte homeostasis, aging, and pathology. Cardiovasc Res 2005; 68(3): 355-65.
88. Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J. Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol 2011; 106(6): 1173-91.
89. Nair S, Ren J. Autophagy and cardiovascular aging: Lesson learned from rapamycin. Cell Cycle 2012; 11(11): 2092-9.
90. Han X, Turdi S, Hu N, Guo R, Zhang Y, Ren J. Influence of longterm caloric restriction on myocardial and cardiomyocyte contractile function and autophagy in mice. J Nutr Biochem 2012 Mar 21.
91. Giricz Z, Mentzer RM, Jr., Gottlieb RA. Autophagy, Myocardial Protection and the Metabolic Syndrome. J Cardiovasc Pharmacol 2012 Apr 2.
92. Sciarretta S, Volpe M, Sadoshima J. Is reactivation of autophagy a possible therapeutic solution for obesity and metabolic syndrome? Autophagy 2012; 8(8).
93. Xie Z, Lau K, Eby B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011; 60(6): 1770-8.
94. Sciarretta S, Zhai P, Shao D, et al. Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome. Circulation 2012; 125(9): 1134-46.
95. Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans 2007; 35(Pt 5): 1147-50.
96. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009; 20(6): 295-302.
97. de Haan JB, Cooper ME. Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunction. Front Biosci (Schol Ed) 2011; 3: 709-29.
98. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 2003; 52(9): 2346-52.
99. Meigs JB, Larson MG, Fox CS, Keaney JF, Jr., Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 2007; 30(10): 2529-35.
100. Cao J, Sodhi K, Puri N, Monu SR, Rezzani R, Abraham NG. High fat diet enhances cardiac abnormalities in SHR rats: Protective role of heme oxygenase-adiponectin axis. Diabetol Metab Syndr 2011; 3(1): 37.
101. Saraiva RM, Minhas KM, Zheng M, Pitz E, Treuer A, Gonzalez D, et al. Reduced neuronal nitric oxide synthase expression contributes to cardiac oxidative stress and nitroso-redox imbalance in ob/ob mice. Nitric Oxide 2007; 16(3): 331-8.
102. Ballal K, Wilson CR, Harmancey R, Taegtmeyer H. Obesogenic high fat western diet induces oxidative stress and apoptosis in rat heart. Mol Cell Biochem 2010; 344(1-2): 221-30.
103. Serpillon S, Floyd BC, Gupte RS, et al. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 2009; 297(1): H153-62.
104. Matsuzawa A, Ichijo H. Stress-responsive protein kinases in redoxregulated apoptosis signaling. Antioxid Redox Signal 2005; 7(3-4): 472-81.
105. Erickson JR, Joiner ML, Guan X, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008; 133(3): 462-74.
106. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 2011; 50(3): 408-16.
107. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol 2004; 555(Pt 1): 1-13.
108. Golden TR, Hinerfeld DA, Melov S. Oxidative stress and aging: beyond correlation. Aging Cell 2002; 1(2): 117-23.
109. Boveris A. Determination of the production of superoxide radicals and hydrogen peroxide in mitochondria. Methods Enzymol 1984; 105: 429-35.
110. Han D, Antunes F, Canali R, Rettori D, Cadenas E. Voltagedependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J Biol Chem 2003; 278(8): 5557-63.
111. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem 2002; 277(47): 44784-90.
112. Starkov AA, Fiskum G, Chinopoulos C, et al. Mitochondrial alphaketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci 2004; 24(36): 7779-88.
113. Brand MD. The sites and topology of mitochondrial superoxide production. Exp Gerontol 2010; 45(7-8): 466-72.
114. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969; 244(22): 6049-55.
115. Barra D, Schinina ME, Simmaco M, et al. The primary structure of human liver manganese superoxide dismutase. J Biol Chem 1984; 259(20): 12595-601.
116. Patenaude A, Ven Murthy MR, Mirault ME. Mitochondrial thioredoxin system: effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis. J Biol Chem 2004; 279(26): 27302-14.
117. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A 2006; 103(8): 2653-8.
118. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 2011; 51(7): 1289-301.
119. Rosen P, Osmers A. Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose. Horm Metab Res 2006; 38(9): 575-86.
120. Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006; 49(6): 1434-46.
121. Feillet-Coudray C, Sutra T, Fouret G, et al. Oxidative stress in rats fed a high-fat high-sucrose diet and preventive effect of polyphenols: Involvement of mitochondrial and NAD(P)H oxidase systems. Free Radic Biol Med 2009; 46(5): 624-32.
122. Letavic MA, Keith JM, Ly KS, et al. Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors. Bioorg Med Chem Lett 2007; 17(9): 2566-9.
123. Matsushima S, Kinugawa S, Yokota T, et al. Increased myocardial NAD(P)H oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes. Am J Physiol Heart Circ Physiol 2009; 297(1): H409-16.
124. Roe ND, Thomas DP, Ren J. Inhibition of NADPH oxidase alleviates experimental diabetes-induced myocardial contractile dysfunction. Diabetes Obes Metab 2011; 13(5): 465-73.
125. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The reninangiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 302(6): H1219-30.
126. Zhang GX, Lu XM, Kimura S, Nishiyama A. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogenactivated protein kinase activation. Cardiovasc Res 2007; 76(2): 204-12.
127. Wang Q, Sun Y, Ma A, Li Y, Han X, Liang H. Effects of vitamin E on plasma lipid status and oxidative stress in Chinese women with metabolic syndrome. Int J Vitam Nutr Res 2010; 80(3): 178-87.
128. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347(9004): 781-6.
129. Lavie CJ, Milani JN. Do antioxidant vitamins ameliorate the beneficial effects of exercise training on insulin sensitivity? J Cardiopulm Rehabil Prev 2011; 31(4): 211-6.
130. Manning PJ, Sutherland WH, Williams SM, et al. The effect of lipoic acid and vitamin E therapies in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2012 Mar 6.
131. Debreceni B, Debreceni L. Why Do Homocysteine-Lowering B Vitamin and Antioxidant E Vitamin Supplementations Appear To Be Ineffective in the Prevention of Cardiovascular Diseases? Cardiovascular Therapeutics 2011: no-no.
132. Avignon A, Hokayem M, Bisbal C, Lambert K. Dietary antioxidants: Do they have a role to play in the ongoing fight against abnormal glucose metabolism? Nutrition 2012; 28(7-8): 715-21.
133. Wang H, Yang YJ, Qian HY, Zhang Q, Xu H, Li JJ. Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev 2012; 17(3): 437-48.
134. Qin F, Siwik DA, Luptak I, et al. The Polyphenols Resveratrol and S17834 Prevent the Structural and Functional Sequelae of Diet-Induced Metabolic Heart Disease in Mice/Clinical Perspective. Circulation 2012; 125(14): 1757-64.
135. Robich MP, Osipov RM, Chu LM, et al. Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur J Pharmacol 2011; 664(1-3): 45-53.
136. Bagul PK, Middela H, Matapally S, et al. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 2012 May 22(0).
137. Liu L, Wang Y, Lam KS, Xu A. Moderate wine consumption in the prevention of metabolic syndrome and its related medical complications. Endocr Metab Immune Disord Drug Targets 2008 Jun; 8(2): 89-98.
138. Timmers S, Konings E, Bilet L, et al. Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans. Cell Metabolism 2011; 14(5): 612-22.
139. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59(3): 554-63.
140. Penumathsa SV, Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 2009; 87(4): 275-86.
141. Guo H, Ling W, Wang Q, Liu C, Hu Y, Xia M. Cyanidin 3-glucoside protects 3T3-L1 adipocytes against H2O2-or TNFalpha-induced insulin resistance by inhibiting c-Jun NH2-terminal kinase activation. Biochem Pharmacol 2008; 75(6): 1393-401.
142. Qin Y, Xia M, Ma J, et al. Anthocyanin supplementation improves serum LDL-and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. The American Journal of Clinical Nutrition 2009; 90(3): 485-92.
143. Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a highcardiovascular disease risk phenotype: a double-blinded, placebocontrolled cross-over study. The British journal of nutrition 2009; 102(7): 1065-74.
144. Panchal SK, Poudyal H, Brown L. Quercetin Ameliorates Cardiovascular, Hepatic, and Metabolic Changes in Diet-Induced Metabolic Syndrome in Rats. J Nutrition 2012; 142(6): 1026-32.
145. Xia X, Weng J. Targeting metabolic syndrome: candidate natural agents. J Diabetes 2010; 2(4): 243-9.
146. Subramanian S, Kalyanaraman B, Migrino RQ. Mitochondrially targeted antioxidants for the treatment of cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2010; 5(1): 54-65.
147. Ramos-Marquez ME, Siller-Lopez F. Current antioxidant molecular therapies for oxidative stress-related ailments. Current gene therapy 2008; 8(4): 256-63.
148. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440(7086): 944-8.
149. Hoehn KL, Salmon AB, Hohnen-Behrens C, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci U S A 2009; 106(42): 17787-92.
150. Saito Y, Fukuhara A, Nishio K, et al. Characterization of cellular uptake and distribution of coenzyme Q10 and vitamin E in PC12 cells. The Journal of Nutritional Biochemistry 2009; 20(5): 350-7.
151. Huynh K, Kiriazis H, Du XJ, et al. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 2012; 55(5): 1544-53.
152. Huynh K, Kiriazis H, Du XJ, et al. Coenzyme Q 10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 2012; 55(5): 1544-53.
153. Kocharian A, Shabanian R, Rafiei-Khorgami M, Kiani A, Heidari-Bateni G. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young 2009; 19(05): 501-6.
154. Young JM, Florkowski CM, Molyneux SL, et al. A Randomized, Double-Blind, Placebo-Controlled Crossover Study of Coenzyme Q10 Therapy in Hypertensive Patients With the Metabolic Syndrome. Am J Hypertens 2012; 25(2): 261-70.
155. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2008(2): CD007176.
156. Rodriguez-Cuenca S, Cochemé HM, Logan A, et al. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radical Biology and Medicine 2010; 48(1): 161-72.
157. Smith RA, Murphy MP. Mitochondria-targeted antioxidants as therapies. Discov Med 2011; 11(57): 106-14.
158. Adlam VJ, Harrison JC, Porteous CM, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 2005; 19(9): 1088-95.
159. Mercer JR, Yu E, Figg N, et al. The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+/-/ApoE-/-mice. Free Radic Biol Med 2012; 52(5): 841-9.
160. Pung YF, Rocic P, Murphy MP, et al. Resolution of Mitochondrial Oxidative Stress Rescues Coronary Collateral Growth in Zucker Obese Fatty Rats. Arteriosclerosis, Thrombosis, and Vascular Biology 2012; 32(2): 325-34.
161. Dai D-F, Chen T, Szeto H, et al. Mitochondrial Targeted Antioxidant Peptide Ameliorates Hypertensive Cardiomyopathy. J Am College Cardiol 2011; 58(1): 73-82.
162. Kloner RA, Hale SL, Dai W, et al. Reduction of Ischemia/Reperfusion Injury With Bendavia, a Mitochondria-Targeting Cytoprotective Peptide. J Am Heart Association 2012; 1(3).
163. Chen M, Liu B, Gao Q, Zhuo Y, Ge J. Mitochondria-Targeted Peptide MTP-131 Alleviates Mitochondrial Dysfunction and Oxidative Damage in Human Trabecular Meshwork Cells. Investigative Ophthalmol Visual Sci 2011; 52(10): 7027-37.
164. Sloan RC, Moukdar F, Frasier CR, et al. Mitochondrial permeability transition in the diabetic heart: Contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury. J Mol Cellular Cardiol 2012; 52(5): 1009-18.
165. Lyamzaev K, Pustovidko A, Simonyan R, et al. Novel Mitochondria-Targeted Antioxidants: Plastoquinone Conjugated with Cationic Plant Alkaloids Berberine and Palmatine. Pharm Res 2011; 28(11): 2883-95.
166. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006; 55(3): 798-805.
167. Dong F, Li Q, Sreejayan N, Nunn JM, Ren J. Metallothionein Prevents High-Fat Diet-Induced Cardiac Contractile Dysfunction. Diabetes 2007 September 2007; 56(9): 2201-12.
168. Ye G, Metreveli NS, Donthi RV, et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004; 53(5): 1336-43.
169. Bruno RM, Daghini E, Ghiadoni L, et al. Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. Am J Clin Nutr 2012 Jun 13.
170. Feng B, Chen S, Chiu J, George B, Chakrabarti S. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. American journal of physiology Endocrinology and metabolism. [Research Support, Non-U.S. Gov't] 2008; 294(6): E1119-26.
171. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005; 27(2): 119-30.
172. Hardeland R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2005; 2: 22.
173. Reiter RJ, Manchester LC, Tan DX. Neurotoxins: free radical mechanisms and melatonin protection. Curr Neuropharmacol 2010; 8(3): 194-210.
174. Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC, et al. Melatonin--a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci 1994; 738: 419-20.
175. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesityassociated abnormalities? Acta Physiol (Oxf) 2012; 205(2): 209-23.
176. Kolar F, Jezkova J, Balkova P, et al. Role of oxidative stress in PKC-delta upregulation and cardioprotection induced by chronic intermittent hypoxia. Am J Physiol Heart Circ Physiol 2007; 292(1): H224-30.
177. Tsujita K, Shimomura H, Kawano H, et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 2004; 94(4): 481-4.
178. Kikuchi K, Uchikado H, Miyagi N, et al. Beyond neurological disease: new targets for edaravone (Review). International journal of molecular medicine 2011; 28(6): 899-906.
179. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009; 119(3): 573-81.
180. Zhao K, Zhao G-M, Wu D, et al. Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury. J Biological Chem 2004; 279(33): 34682-90.